Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.41 |
| ▸ | JAK2 | O60674 | 5/20 | 0.40 |
| ▸ | JAK1 | P23458 | 5/20 | 0.40 |
| ▸ | TYK2 | P29597 | 5/20 | 0.40 |
| ▸ | JAK3 | P52333 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21737988 | 1.00 | SMYD3 (0.41) | SMYD3JAK2JAK1TYK2JAK3 | |
| SCHEMBL21080705 | 0.85 | SMN1; SMN2 (0.39) | POLBNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL21080706 | 0.85 | SMN1; SMN2 (0.39) | POLBNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL21797341 | 0.84 | SMN1; SMN2 (0.38) | POLBNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL21738137 | 0.84 | SMN1; SMN2 (0.38) | POLBNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL21737987 | 0.84 | SMN1; SMN2 (0.38) | POLBNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL21737983 | 0.81 | LIPG (0.37) | JAK2JAK1TYK2JAK3POLB | |
| SCHEMBL21737888 | 0.81 | LIPG (0.37) | JAK2JAK1TYK2JAK3POLB | |
| SCHEMBL21737881 | 0.81 | SMN1; SMN2 (0.41) | SMYD3POLBRAB9AHPGDSMN1; SMN2 | |
| SCHEMBL21797483 | 0.79 | SMN1; SMN2 (0.35) | POLBHPGDSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020036986-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | IRAK4, IRAK3, IRAK2 | SMYD3 2810/4885JAK2 15/4885JAK1 12/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | SMYD3 2853/4885JAK2 16/4885JAK1 12/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | SMYD3 2853/4885JAK2 16/4885JAK1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.